Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Antonios Koutras -- 1492 2023-01-12 10:43:33 |
2 update references and layout Amina Yu + 2 word(s) 1494 2023-01-13 02:56:08 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Fasoulakis, Z.;  Koutras, A.;  Ntounis, T.;  Antsaklis, P.;  Theodora, M.;  Valsamaki, A.;  Daskalakis, G.;  Kontomanolis, E.N. Inflammatory Molecules Responsible for Preterm Birth. Encyclopedia. Available online: https://encyclopedia.pub/entry/40111 (accessed on 27 March 2026).
Fasoulakis Z,  Koutras A,  Ntounis T,  Antsaklis P,  Theodora M,  Valsamaki A, et al. Inflammatory Molecules Responsible for Preterm Birth. Encyclopedia. Available at: https://encyclopedia.pub/entry/40111. Accessed March 27, 2026.
Fasoulakis, Zacharias, Antonios Koutras, Thomas Ntounis, Panos Antsaklis, Marianna Theodora, Asimina Valsamaki, George Daskalakis, Emmanuel N. Kontomanolis. "Inflammatory Molecules Responsible for Preterm Birth" Encyclopedia, https://encyclopedia.pub/entry/40111 (accessed March 27, 2026).
Fasoulakis, Z.,  Koutras, A.,  Ntounis, T.,  Antsaklis, P.,  Theodora, M.,  Valsamaki, A.,  Daskalakis, G., & Kontomanolis, E.N. (2023, January 12). Inflammatory Molecules Responsible for Preterm Birth. In Encyclopedia. https://encyclopedia.pub/entry/40111
Fasoulakis, Zacharias, et al. "Inflammatory Molecules Responsible for Preterm Birth." Encyclopedia. Web. 12 January, 2023.
Inflammatory Molecules Responsible for Preterm Birth
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells12020209

It is estimated that inflammation at the placental–maternal interface is directly responsible for or contributes to the development of 50% of all premature deliveries. Chorioamnionitis, also known as the premature rupture of the amniotic membrane in the mother, is the root cause of persistent inflammation that preterm newborns experience. Beyond contributing to the onset of early labor, inflammation is a critical element in advancing several conditions in neonates, including necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia, intraventricular hemorrhage, retinopathy of prematurity and periventricular leukomalacia. Notably, the immune systems of preterm infants are not fully developed; immune defense mechanisms and immunosuppression (tolerance) have a delicate balance that is easily upset in this patient category.

preterm birth cervical insufficiency inflammation interleukins

1. Preterm Birth and Immune Changes

As elucidated in the preamble, preterm births (PTB) pertains to birth that occurs before 37 weeks of gestation, a definition that the World Health Organization has endorsed. Premature births accounted for 11.1% of all deliveries in 2010, accounting for 14.9 million births worldwide. Preterm birth accounts for about 5% of births in European countries and approximately 18% in African countries. Children born prematurely have an augmented risk of mortality before their fifth year of life. The financial burden of neonatal intensive care is substantial, and its emotional toll on families can last for years [1][2].
The deposition of paternal antigens on fetal tissues relies on feto-maternal immunological tolerance, as shown in a number of studies. The uterus is invaded by fetal trophoblast cells. During first contact with seminal fluid during copulation, the mother’s immune system recognizes and reacts to fetal or paternal antigens; this process is repeated several times throughout pregnancy. By stimulating the production of proinflammatory cytokines and the recruitment of leukocytes to the uterine lining, the inclusion of cytokines, chemokines and prostaglandins in seminal fluid makes implantation itself an inflamed process. This inflammation must subside, and a tolerogenic environment must be developed around the time of implantation [2][3].
Among the many processes set in motion to create this tolerogenic setting are the release of anti-inflammatory chemicals such as TGF and the generation of specialist anti-inflammatory T cells designated as CD4+FOXP3+ regulatory T (Treg) cells, which restrain anti-fetal inflammatory immune responses [4][5][6]. Tolerogenic dendritic cells (DCs), which are only found in the decidua, play a crucial role in forming regulatory T cells (Tregs) by cross-presenting fetal antigens to maternal CD4+ T cells. In a two-way street of immunomodulation, regulatory T cells (Tregs) engage with dendritic cells (DCs) and macrophages (M) to induce tolerogenic phenotypes in both cell types. By preventing T effector (Teff) cell responses and maintaining anergy in the pool of T conventional (Tcon) cells that would otherwise grow into Teff cells, Treg cells play a vital role in immunological defense against anti-fetal reactions. Furthermore, placental cells contribute to a tolerogenic microenvironment by increasing operationally repressive CD4+FOXP3+ Treg cells and restricting the stimulation of T helper (Th)1-, Th17- and Th2cytokine-producing Teff cells [7][8][9]. These cytokines are released by placental cells in addition to IL-10 and trophoblast-derived colony-stimulating factor (CSF)1 (formerly M-CSF) [4][5][6][7][8][9][10][11][12][13].

2. Immuno-Inflammation and Preterm Birth

What sets apart term and preterm labor could be an early imbalance of decidual inflammatory signals or a powerful aberrant stimulation (internal or external) that initiates inflammatory pathways. Anti-inflammatory mediators (including IL-10 and IL-4), in contrast to proinflammatory mediators (IL-1, IL-6, IL-8, TNF- and INF-), are downregulated in PTB [14][15]. In actuality, IL-10 has a major impact on preterm birth; it is generally thought of as a cytokine that helps keep the neonate inside the uterus. The symptoms of PTB syndrome are placental malfunction, early uterine contractions, membrane rupture and cervical dilatation. Additionally, myometrial, cervical, endometrial, decidual and placental pathology have all been linked to PTB [16][17]. Placental lesions indicative of maternal vascular under-perfusion are seen in approximately 30% of patients with PTB. Therefore, PTB may be considered a disorder similar to preeclampsia induced by defective deep placentation [18][19].
Furthermore, how a mother handles stress, infections and her diet impacts her developing child’s immune system, leading to impaired immune tolerance and an inflammatory response. Bacterial flora in the placenta is similar to that found in the mouth rather than the vagina. Inflammation and infection have been tied to as much as one-fourth of all preterm births. The unique triple “I” approach, which represents intrauterine inflammation, infection or both, emphasizes the fact that intrauterine inflammation can manifest itself in the absence of overtly harmful intrauterine infection. Furthermore, women with a short cervix are more likely to experience sterile intra-amniotic inflammation (10%) than microbial-associated intra-amniotic inflammation [20]. Despite this, both trigger the same cytokine mediators. It has been found that IL-6 and IL-1β are the two most essential uterine mediators throughout the transition period. High amounts of IL-6 are present at the start of labor, suggesting that it plays a role in implantation, pregnancy and birth. It is also implicated in stimulating amnion and decidual cells, culminating in increased prostaglandin production [21][22].
In addition, IL-6 in vaginal fluid has been extensively studied as a diagnostic biomarker of preterm delivery. There is a correlation between IL-6 levels, a marker of inflammation, and perinatal death and morbidity [18][21]. However, amniotic fluid IL-6 as a diagnostic marker for intraamniotic inflammation has been criticized by some researchers, who contend that this method fails to capture the full scope of intrauterine inflammation. Nonetheless, IL-1β affects the regulation of genes involved in inflammation and labor in the uterus. Furthermore, IL-1 promotes progesterone (P4) withdrawal by elevating nuclear progesterone receptor A, and it is a powerful activator of prostaglandin production by inducing COX2 [17]. In addition, IL-1-related pathways are elevated throughout the third trimester of pregnancy in women who give birth prematurely [18][21].
PTB is linked to increased choriodecidual inflammation, as well as increased M1 macrophages and NK cells when viewed from the scope of cells. PAMPs (infectious stimuli) or DAMPs (sterile stimuli) are two possible ways that a detrimental state can activate the innate system. The stress-exposed uterus, the developing fetus or the aging placenta can all release DAMPs. Some researchers have revealed that cfDNA triggers sterile inflammation and that fetal membrane aging is a crucial indicator at the commencement of labor. As a result of this innate stimulation, TLRs are activated, which in turn activate the production of proinflammatory cytokines, chemokines and leukocytes, ultimately resulting in the initiation of labor. Spontaneous PTB occurs if the deregulation of decidual inflammatory signaling occurs at an early stage. Mid-trimester endometrium inflammation, triggered by factors such as intrauterine infection or placental abruption, has also been linked to PTB. Moreover, smoking, anemia, a short cervix, a history of genital tract infections, racial/ethnic background and low or high birth weight may all be indicators of a lack of protective immunity inside the uterine tissues [17][18].
Genetic predisposition has been linked to PTB because it clusters in families, is highly heritable, can be identified through genetic susceptibility markers and reveals racial disparities. Women born prematurely have an increased risk of having premature kids in the future. Furthermore, at least one-third of PTB can be attributed to genetics, according to twin studies. An examination of maternal data revealed an upregulation of innate immunity-related genes and a downregulation of adaptive immunity-related genes, among the 210 genes shown to be differently expressed in PTB. Among these genes, 18 showed trimester-specific expression differences (mostly during the second trimester). It was discovered that the immune-related proteins IL-1R1 and tissue factor pathway inhibitor are differentially expressed and released longitudinally [19][20].
As a result, PTB has a polygenic foundation, meaning that it is caused by uncommon mutations or harmful variations in several genes associated with innate immunity and host defense systems against microorganisms and their toxic materials. Thus, inflammatory genes are activated and accelerate these processes. Furthermore, there are inherited polymorphisms that modify the inflammatory response in PTB, and there are identity genetic variations that alter the inflammatory response in PTB. TLR5, for example, is increased in the mother but downregulated in the fetus, a finding that is consistent with other recent studies. Epigenetic changes or variations due to incorrect fetal programming have also been linked to adult-onset illnesses in preterm infants [21][22][23][24][25].
Hormones that stimulate labor and reproduction inflammatory responses during pregnancy are aided by gestational hormones. For example, estrogen suppresses proinflammatory cytokines (IL-1; TNF-α; IFN-γ) and promotes anti-inflammatory IL-10, IL-4 and TGF-β. Nonetheless, IL-10 has been regarded as part of a pro-labor inflammatory response, playing a role in labor that varies with the tissue involved and can be either active or tolerant. Anti-inflammatory progesterone also helps stop uterine contractions and shields the developing fetus from harm. However, peripheral progesterone levels in humans are remarkable in that they do not fluctuate during pregnancy and only decrease after the baby and placenta have been delivered. In the last weeks of pregnancy, serum P4 levels rise, but the hormone’s ability to sustain a pregnancy weakens. This suggests that variations in labor may be attributable to the expression of nPRs (nuclear progesterone receptors) A and B. The primary receptor, nPRB, has anti-inflammatory properties that delay or stop labor and delivery [26][27][28].

References

  1. Blencowe, H.; Cousens, S.; Oestergaard, M.Z.; Chou, D.; Moller, A.B.; Narwal, R.; Adler, A.; Garcia, C.V.; Rohde, S.; Say, L.; et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. Lancet 2012, 379, 2162–2172.
  2. Jiang, M.; Mishu, M.M.; Lu, D.; Yin, X. A case control study of risk factors and neonatal outcomes of preterm birth. Taiwan. J. Obstet. Gynecol. 2018, 57, 814–818.
  3. Peacock, J.L.; Marston, L.; Marlow, N.; Calvert, S.A.; Greenough, A. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr. Res. 2012, 71, 305–310.
  4. Li, Y.; Yan, J.; Chang, H.M.; Chen, Z.J.; Leung, P.C. Roles of TGF-β superfamily proteins in extravillous trophoblast invasion. Trends Endocrinol. Metab. 2021, 32, 170–189.
  5. Guerin, L.R.; Moldenhauer, L.M.; Prins, J.R.; Bromfield, J.J.; Hayball, J.D.; Robertson, S.A. Seminal fluid regulates accumulation of FOXP3+ regulatory T cells in the preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-mediated recruitment. Biol. Reprod. 2011, 85, 397–408.
  6. Robertson, S.A.; Care, A.S.; Moldenhauer, L.M. Regulatory T cells in embryo implantation and the immune response to pregnancy. J. Clin. Investig. 2018, 128, 4224–4235.
  7. Samstein, R.M.; Josefowicz, S.Z.; Arvey, A.; Treuting, P.M.; Rudensky, A.Y. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 2012, 150, 29–38.
  8. Rowe, J.H.; Ertelt, J.M.; Xin, L.; Way, S.S. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 2012, 490, 102–106.
  9. Chen, T.; Darrasse-Jèze, G.; Bergot, A.S.; Courau, T.; Churlaud, G.; Valdivia, K.; Strominger, J.L.; Ruocco, M.G.; Chaouat, G.; Klatzmann, D. Self-specific memory regulatory T cells protect embryos at implantation in mice. J. Immunol. 2013, 191, 2273–2281.
  10. Petroff, M.G.; Nguyen, S.L.; Ahn, S.H. Fetal-placental antigens and the maternal immune system: Reproductive immunology comes of age. Immunol. Rev. 2022, 308, 25–39.
  11. Sorgdrager, F.J.; Naudé, P.J.; Kema, I.P.; Nollen, E.A.; Deyn, P.P. Tryptophan metabolism in inflammaging: From biomarker to therapeutic target. Front. Immunol. 2019, 10, 2565.
  12. Kalekar, L.A.; Schmiel, S.E.; Nandiwada, S.L.; Lam, W.Y.; Barsness, L.O.; Zhang, N.; Stritesky, G.L.; Malhotra, D.; Pauken, K.E.; Linehan, J.L.; et al. CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors. Nat. Immunol. 2016, 17, 304–314.
  13. Svensson-Arvelund, J.; Mehta, R.B.; Lindau, R.; Mirrasekhian, E.; Rodriguez-Martinez, H.; Berg, G.; Lash, G.E.; Jenmalm, M.C.; Ernerudh, J. The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages. J. Immunol. 2015, 194, 1534–1544.
  14. Kalagiri, R.R.; Carder, T.; Choudhury, S.; Vora, N.; Ballard, A.R.; Govande, V.; Drever, N.; Beeram, M.R.; Uddin, M.N. Inflammation in Complicated Pregnancy and Its Outcome. Am. J. Perinatol. 2016, 33, 1337–1356.
  15. Bonney, E.A.; Johnson, M.R. The role of maternal T cell and macrophage activation in preterm birth: Cause or consequence? Placenta 2019, 79, 53–61.
  16. Di Renzo, G.C.; Cabero Roura, L.; Facchinetti, F.; Helmer, H.; Hubinont, C.; Jacobsson, B.; Jørgensen, J.S.; Lamont, R.F.; Mikhailov, A.; Papantoniou, N.; et al. Preterm Labor and Birth Management: Recommendations from the European Association of Perinatal Medicine. J. Matern.-Fetal Neonatal. Med. 2017, 30, 2011–2030.
  17. Di Renzo, G.C.; Tosto, V.; Giardina, I. The biological basis and prevention of preterm birth. Best Pract. Res. Clin. Obstet. Gynaecol. 2018, 52, 13–22.
  18. Gilman-Sachs, A.; Dambaeva, S.; Salazar Garcia, M.D.; Hussein, Y.; Kwak-Kim, J.; Beaman, K. Inflammation induced preterm labor and birth. J. Reprod. Immunol. 2018, 129, 53–58.
  19. Cappelletti, M.; Della Bella, S.; Ferrazzi, E.; Mavilio, D.; Divanovic, S. Inflammation and preterm birth. J Leukoc Biol. 2016, 99, 67–78.
  20. Menon, R.; Behnia, F.; Polettini, J.; Richardson, L.S. Novel pathways of inflammation in human fetal membranes associated with preterm birth and preterm pre-labor rupture of the membranes. Semin. Immunopathol. 2020, 42, 431–450.
  21. Leimert, K.B.; Xu, W.; Princ, M.M.; Chemtob, S.; Olson, D.M. Inflammatory Amplification: A Central Tenet of Uterine Transition for Labor. Front. Cell Infect. Microbiol. 2021, 11, 660983.
  22. Patel, B.; Peters, G.A.; Skomorovska-Prokvolit, Y.; Yi, L.; Tan, H.; Yousef, A.; Wang, J.; Mesiano, S. Control of progesterone receptor-A transrepressive activity in myometrial cells: Implications for the control of human parturition. Reprod. Sci. 2018, 25, 214–221.
  23. Triggs, T.; Kumar, S.; Mitchell, M. Experimental drugs for the inhibition of preterm labor. Expert. Opin. Investig. Drugs. 2020, 29, 507–523.
  24. Boyle, A.K.; Rinaldi, S.F.; Norman, J.E.; Stock, S.J. Preterm birth: Inflammation, fetal injury and treatment strategies. J. Reprod. Immunol. 2017, 119, 62–66.
  25. Zierden, H.C.; Shapiro, R.L.; De Long, K.; Carter, D.M.; Ensign, L.M. Next generation strategies for preventing preterm birth. Adv. Drug. Deliv. Rev. 2021, 174, 190–209.
  26. Singh, N.; Bonney, E.; McElrath, T.; Lamont, R.F.; Shennan, A.; Gibbons, D.; Preterm Birth International collaborative (PREBIC). Prevention of preterm birth: Proactive and reactive clinical practice-are we on the right track? Placenta 2020, 98, 6–12.
  27. Gomez-Lopez, N.; Garcia-Flores, V.; Chin, P.Y.; Groome, H.M.; Bijland, M.T.; Diener, K.R.; Romero, R.; Robertson, S.A. Macrophages exert homeostatic actions in pregnancy to protect against preterm birth and fetal inflammatory injury. JCI Insight. 2021, 6, e146089.
  28. Combs, C.A.; Gravett, M.; Garite, T.J.; Hickok, D.E.; Lapidus, J.; Porreco, R.; Rael, J.; Grove, T.; Morgan, T.K.; Clewell, W.; et al. ProteoGenix/Obstetrix Collaborative Research Network. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. Am. J. Obstet. Gynecol. 2014, 210, 125.e1–125.e15.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Obstetrics & Gynaecology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Zacharias Fasoulakis , Antonios Koutras , Thomas Ntounis , Panos Antsaklis , Marianna Theodora , Asimina Valsamaki , George Daskalakis , Emmanuel N. Kontomanolis
View Times: 586
Revisions: 2 times (View History)
Update Date: 13 Jan 2023
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback